Dexcom | Capitaux Propres Et Réserves



Equity Capital And Reserves Changement Date
Abbott USD 40.03B 468M 2024-12
Align Technology USD 3.85B 92.37M 2024-12
AtriCure USD 460.97M 4.05M 2024-12
Avanos Medical USD 828.5M 401.2M 2024-12
Baxter International USD 6.96B 908M 2024-12
Becton, Dickinson and Co. USD 25.2B 685M 2024-12
Boston Scientific USD 21.77B 1.06B 2024-12
Cooper Companies USD 8.13B 44.1M 2025-01
Dexcom USD 2.1B 123.6M 2024-12
Edwards Lifesciences USD 10B 452.8M 2024-12
Globus Medical USD 4.18B 107.94M 2024-12
Hologic USD 4.77B 356.7M 2024-12
Insulet USD 1.21B 93.6M 2024-12
Integra LifeSciences USD 1.55B 23.69M 2024-12
J&J USD 71.49B 1.33B 2024-12
Masimo USD 1.05B 411.3M 2024-12
Medtronic USD 49.39B 893M 2025-01
Merit Medical Systems USD 1.38B 55.95M 2024-12
Roche Holding CHF 36.16B 3.28B 2024-12
Solventum Corp 2.96B 233M 2024-12
Stryker USD 20.63B 485M 2024-12
Tandem Diabetes Care USD 263.1M 25.39M 2024-12
Teleflex USD 4.28B 203.58M 2024-12
West Pharmaceutical Services USD 2.68B 69.8M 2024-12
Zimmer Biomet Holdings USD 12.47B 93.4M 2024-12



Dexcom Capitaux Propres Et Réserves - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.